BAYTRIL 2.5% ORAL SOLUTION

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baytril 2.5% Oral Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Calves
Exotic Animals (small mammals, reptiles and avian species)
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product is for use in calves in the treatment of infections of the
alimentary and respiratory tracts of bacterial or
mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis,
coli-bacilliosis and salmonellosis), where clinical experience
supported where possible by sensitivity testing of the causal
organism, indicates enrofloxacin as the drug of choice.
The product may also be used in exotic animals (small mammals,
reptiles and avian species) for the treatment of bacterial
infections of the alimentary and respiratory tracts where clinical
experience, supported where possible by sensitivity testing
of the causal organism, indicates enrofloxacin as the drug of choice.
4.3 CONTRAINDICATIONS
The product should not be used for prophylaxis.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
EXOTIC ANIMALS:
Consult the Technical Services Department of Bayer prior to use.
Active Constituents
mg/ml
Enrofloxacin
25.0 ml
Relevant Constituents of the Excipients
Benzyl Alcohol
14.0
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
                                
                                Read the complete document